iPSC-ing into the future of cell therapy: expansion in a hollow-fiber bioreactor

Induced pluripotent stem cell (iPSC)-derived therapies have opened up a new avenue for stem cell research and unique opportunities to shift cell therapy into an allogeneic paradigm. The development of these therapies requires high-quality iPSC banks generated via standardized workflows to minimize starting material bank-to-bank variability.

Two expert scientists will share their long-standing experience working with IPSCs, the associated challenges, and the workflow and protocol optimizations needed to achieve doses relevant for clinical studies or further manufacturing.

They will explain how to move from manual processes to a functionally closed, automated, and scalable system effectively using hollow-fiber perfusion technology to expand iPSCs.

In this webinar you will learn more about:

• Providing a consistent and tailored environment for iPSC expansion by hollow-fiber perfusion technology
• How to increase GMP compliance and process standardization
• How to close the seed train by scaling down on this automated platform
• How to scale up and out to manufacture high-quality iPSC banks

Nathan Frank

Laboratory Scientist IV at Terumo Blood and Cell Technologies

Nate has more than a decade of experience optimizing parameters for cell and gene therapy production and scale-up. He has specialized expertise in hollow-fiber bioreactor process development for a range of cell types aimed at various applications in regenerative medicine and immunotherapy. He is a two-time National Science Foundation fellow and has a passion for teaching and communicating science to a wide range of audiences from established professionals to middle and high school students who are just beginning their scientific journey.

Molly Tregidgo

Associate Senior Scientist - Technology, Process & Innovation, Cell & Gene Therapy at Catapult

Molly Tregidgo obtained her degree in Biochemical Engineering from University College London in 2015, where she later completed her EngD investigating novel scale-down models for perfusion bioprocess development. She joined Cell and Gene Therapy Catapult (CGTC) in 2021, as a Bioprocessing Scientist.

At CGTC she works in Upstream Bioprocessing with allogeneic cell therapies across a range of bioreactor platforms, specialising in scale-up/down of cell culture processes.

Watch now

SPEAKERS

Nathan Frank

Laboratory Scientist IV at Terumo Blood and Cell Technologies

Molly Tregidgo

Associate Senior Scientist - Technology, Process & Innovation, Cell & Gene Therapy at Catapult

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 60

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 39

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 38

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 31

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 25

Days

Register